Mykofenolatmofetil Actavis (Mycophenolate Mofetil)

Mycophenolate mofetil selectively and reversibly inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH). This blocks the synthesis of guanosine nucleotides, which are essential for the proliferation of T‑ and B‑lymphocytes, thereby suppressing the immune response.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, weight, renal function and other individual factors. Patients should follow the prescriber’s instructions exactly.

Mykofenolatmofetil Actavis is classified as pregnancy category D, indicating evidence of risk to the fetus. It should be avoided in pregnancy unless the potential benefit justifies the risk. Breastfeeding is not recommended because the drug is excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, mycophenolate mofetil offers a different mechanism—IMPDH inhibition—resulting in selective suppression of lymphocyte proliferation. It is often used in combination regimens to achieve synergistic immunosuppression while potentially reducing the dose‑related toxicity of each agent.

Store the product at ambient temperature, below 25 °C. Keep it in the original packaging to protect from moisture and light, and avoid exposure to extreme heat or humidity.

Mykofenolatmofetil Actavis is taken orally, usually as tablets or capsules, with or without food as directed by the prescriber. The exact administration instructions, including timing relative to other medications, should be followed as per the healthcare provider’s guidance.

Serious risks include severe infections, opportunistic infections such as progressive multifocal leukoencephalopathy, bone‑marrow suppression leading to leukopenia or anemia, hepatic toxicity, and an increased risk of certain malignancies. Patients should be monitored closely for these events.

Mykofenolatmofetil Actavis is contraindicated in patients with known hypersensitivity to mycophenolate mofetil or any of its excipients, in pregnant women unless absolutely necessary, and in individuals with severe, uncontrolled infections. Caution is also advised for patients with significant renal or hepatic impairment.